Analysis of the cilostazol safety database.

Keyphrases

• Cilostazol 100%
• Safety Database 100%
• Placebo 58%
• Pentoxifylline 41%
• Myocardial Infarction 17%
• Patient Exposure 17%
• United States 11%
• Cardiovascular Morbidity 11%
• Diarrhea 11%
• Headache 11%
• Intermittent Claudication 11%
• Controlled Experiment 5%
• Cardiovascular Events 5%
• Palpation 5%
• Pharyngitis 5%
• Treatment Group 5%
• Safety Profile 5%
• Nausea 5%
• All-cause Mortality 5%
• Phosphodiesterase Inhibitors 5%
• Cardiovascular Mortality 5%
• Risk-benefit Ratio 5%
• Mortality Risk 5%
• Gastrointestinal Problems 5%
• Safety Data 5%
• Stroke Incidence 5%
• Acceptable Risk 5%
• Morbidity Risk 5%
• Post-marketing Surveillance 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Cilostazol 100%
• Placebo 58%
• Pentoxifylline 41%
• Heart Infarction 17%
• Diarrhea 11%
• Headache 11%
• Cerebrovascular Accident 11%
• Intermittent Claudication 11%
• Treatment Group 5%
• Controlled Clinical Trial 5%
• Pharyngitis 5%
• All Cause Mortality 5%
• Nausea 5%
• Gastrointestinal Symptom 5%
• Postmarketing Surveillance 5%
• Heart Palpitation 5%
• Phosphodiesterase III Inhibitor 5%